Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer

Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately held San Diego-based pharmaceutical company developing novel small molecules against protein targets involved in fibroproliferative disease, today announced the two companies will merge.

Galecto Appoints New Chair and Strengthens Board of Directors

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today that its Board of Directors has appointed Amit Munshi as its new Chairman. Galecto also announced the appointment of David Shapiro MD, the former Chief Medical Officer of Intercept Pharmaceuticals, to its Board of Directors.

Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis; Recruitment Remains on Track Despite COVID-19 Crisis

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today that it has recruited more than 150 patients in its Phase 2b GALACTIC-1 study of GB0139 in Idiopathic Pulmonary Fibrosis (IPF).

Galecto presents GB0139 preclinical and clinical data on anti-fibrotic activity as online Experimental Biology 2020 poster

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced new data describing the preclinical and clinical evidence for anti-fibrotic activity of its lead compound GB0139 (formerly TD139), in an abstract for the Experimental Biology 2020 conference.

Galecto Appoints Jonathan Freve as Chief Financial Officer

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Jonathan Freve, CPA, as its Chief Financial Officer (CFO).

Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical Officer

Galecto, Inc., a leading developer of novel treatments for fibrosis  and cancer, today announces the appointment of the highly experienced industry leader Bertil Lindmark as Chief Medical Officer per February 1, 2020.

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development

Galecto Biotech AB, the leading developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, today announced the successful closing of a €79 million series C financing co-led by Ysios Capital and OrbiMed. New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round. Concurrent with the financing, Karen Wagner (Ysios Capital), Chau Khuong (OrbiMed), Chandra Leo (HBM) and Erez Chimovits (OrbiMed Israel) were appointed to the Galecto Board of Directors.

Galecto Biotech’s Lead Molecule TD139 is Safe, Well Tolerated, with Direct Target Engagement and Biomarker Effects in a Clinical Phase Ib/IIa trial in IPF Patients

Today, Galecto Biotech AB can announce the successful completion of its phase Ib/IIa clinical trial of inhaled TD139. The new drug demonstrates ground-breaking results for patients suffering from Idiopathic Pulmonary Fibrosis (IPF), a chronic and severe disease characterized by a progressive decline in lung function.

FDA approves an IND from Galecto Biotech for TD139 treatment of IPF patients. – Phase Ib/IIa Trial to Start in the UK

Galecto Biotech AB today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for the company’s galectin-3 inhibitor, TD139, for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Simultaneously, the company announced that a phase Ib/IIa trial in IPF patients is due to start shortly in several centers in the United Kingdom (UK).

Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and its Novel Galectin-3 inhibitor in Development for Idiopathic Pulmonary Fibrosis

Bristol-Myers Squibb Company(NYSE: BMY) and Galecto Biotech AB today announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic condition.